symbol |
ALQA |
会社名 | Alliqua BioMedical Inc (アリクア・バイオメディカル) |
分野(sector) |
Health Care
ヘルスケア
|
産業(industry) |
Medical/Dental Instruments
|
業種 |
医療機器_医療用品_ディストリビュ―タ―
医療関連(Health Care)
|
概要 |
事業概要 Alliqua BioMedical Inc. is a regenerative technology company that commercializes regenerative medical products which assist the body in the repair or replacement of soft tissue. The Company develops and manufactures electron-beam cross-linked sheet gels. It serves manufacturers of medical devices cosmeceuticals and other commercial product applications. Its hydrogel platform technology allows manufacturing electron-beam cross-linked sheet gels with or without active ingredients. Through its platform the Company delivers prescription or over-the-counter medications ingredients for wound healing and skin care or other materials. It provides custom hydrogels to the original equipment manufacturer market. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. アリクア・バイオメディカルは米国のバイオ医薬品メ―カ―。創傷ケア技術の開発に重点を置いた高度な医療製品の開発に従事。主な製品には液体状創傷ケア用ドレッシング材「シルバ―シ―ル」と「ハイドレス」がある。湿潤環境を保つ「シルバ―シ―ル」は火傷治療にも効果がある。本社はペンシルベニア州。
|
本社所在地 | 1010 Stony Hill Road Yardley PA 19067 USA |
代表者氏名 | David Ian Johnson David Ian Johnson |
代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者(CEO) |
電話番号 | +1 215-702-8550 |
設立年月日 | 35704 |
市場名 | NASDAQ Small Cap |
ipoyear | ―年 |
従業員数 | 81人 |
url | www.alliqua.com |
nasdaq_url | https://www.nasdaq.com/symbol/alqa |
adr_tso | ― |
EBITDA | EBITDA(百万ドル) -5.35100 |
終値(lastsale) | 2.35 |
時価総額(marketcap) | 11762243.5 |
時価総額 | 時価総額(百万ドル) 10.76120 |
売上高 | 売上高(百万ドル) 11.76600 |
企業価値(EV) | 企業価値(EV)(百万ドル) -0.25980 |
当期純利益 | 当期純利益(百万ドル) -35.60800 |
決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Alliqua Biomedical Inc revenues increased 65% to $1.4M. Net loss before extraordinary items increased 62% to $4.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Loss on early extinguishment of debt increase from $0K to $1.7M (expense). |